Vigobi Drug Shows Promising Results in Treating Type 2 Diabetes and Heart Failure in Obese Patients: Study Finds Fewer Side Effects and Improved Outcomes

A study funded by Novo Nordisk, the maker of the Vigobi drug, examined the effects of the medication on individuals with type 2 diabetes and heart failure who were obese. The research involved 616 participants from various countries worldwide, with one group receiving Vigobi injections while the other received a placebo. Those who received Vigobi showed significant improvements in weight loss, reduction of heart failure symptoms, increased physical endurance, and improvements in biomarkers for inflammation.

The study found that those who took Vigobi experienced fewer side effects, hospitalizations, and emergency visits compared to those who received a placebo. The results suggest that Vigobi is safe and effective for treating a diverse population, including complex patients with diabetes. Dr. Michael Kosybrod, head of the research team, noted that while weight loss may play a role in some positive outcomes seen with Vigobi, it does not account for all of the benefits.

Vigobi is now available in Israel at a monthly cost of NIS 1,250 for the recommended dose. The drug is administered in gradually increasing doses over an extended period or even for life. This new treatment offers hope for patients with limited options for managing their condition.

Heart failure can significantly impair an individual’s ability to carry out everyday tasks. Those affected may experience fatigue, difficulty breathing and may even require oxygen in severe cases. It can lead to hospitalization, disability and death.

A new study funded by Novo Nordisk focused on individuals with type 2 diabetes and heart failure who were obese. The study involved 616 participants from various countries around the world.

One group received the Vigobi injection while another group received a placebo.

Those who received Vigobi showed significant improvements in weight loss, reduction of heart failure symptoms, increased physical endurance and improvements in biomarkers for inflammation.

The study found that participants who received Vigobi experienced fewer side effects, hospitalizations and emergency visits compared to those who received the placebo.

The results suggest that Vigobi is safe and effective treatment for a diverse population including complex patients with diabetes.

Dr. Michael Kosybrod noted that while weight loss may play a role in some positive outcomes seen with Vigobi it does not account for all of them.